Transcutaneous PO2 Monitoring in Infants with Cyanotic Congenital Heart Disease Treated with Prostaglandin E1
Overview
Overview
Journal
Pediatr Cardiol
Specialties
Cardiology & Vascular Diseases
Pediatrics
Pediatrics
Date
1983 Apr 1
PMID
6878077
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
Transcutaneous PO2 (tcPO2) has been shown to closely approximate arterial PO2 (PaO2) in infants with normal oxygenation (PaO2 60-100 mm Hg). During hypoxemia (PaO2 less than 60 mm Hg), or administration of vasoactive drugs, such as tolazoline, correlation is frequently so poor that tcPO2 monitoring is of little value. We examined the relationship of tcPO2 to PaO2 among 6 infants with cyanotic congenital heart disease who were receiving prostaglandin E1 (PGE1). Close, linear correlation was found, even during hypoxemia. We conclude that tcPO2 monitoring has potential clinical value in such patients.
References
1.
Bossi E, Breitenstein M, Lenzin B
. Cutaneous pO2-measurements in newborns with respiratory distress syndrome. Helv Paediatr Acta. 1976; 31(4-5):335-45.
View
2.
Huch R, Huch A, Albani M, Gabriel M, SCHULTE F, Wolf H
. Transcutaneous PO2 monitoring in routine management of infants and children with cardiorespiratory problems. Pediatrics. 1976; 57(5):681-90.
View
3.
Mieth D, Micheli J, Duc G, Ferdico S
. Letter: Reliability of transcutaneous PO2 with Roche Oxygen Monitor 5300 at 44 C in newborn infants with RDS. Pediatrics. 1976; 58(2):299-301.
View
4.
Boyle R, Oh W
. Transcutaneous PO2 monitoring in infants with persistent fetal circulation who are receiving tolazoline therapy. Pediatrics. 1978; 62(4):605-7.
View
5.
Lofgren O, Henriksson P, Jacobson L, Johansson O
. Transcutaneous Po2 monitoring in neonatal intensive care. Acta Paediatr Scand. 1978; 67(6):693-7.
DOI: 10.1111/j.1651-2227.1978.tb16245.x.
View